Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Excretion Balance and PK of Olesoxime in Healthy Volunteers
NCT02835976Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of olesoxime in spinal muscular atrophy (SMA), sponsored by Roche. Primary endpoints: T1/2 of Radiocarbon at 408 hours, Apparent Plasma Clearance (CL/F) of Olesoxime and Any Major Metabolite(s) Identified at 408 hours and 17 more. Started Jul 2014; status: completed.
02
Drugs
olesoxime
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT02835976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02835976.